论文部分内容阅读
目的探讨奥扎格雷钠联合低分子肝素钙治疗进展性脑梗死的临床效果。方法将在本院治疗的进展性脑梗死患者90例随机分为观察组和对照组。对照组给予常规治疗措施,观察组在对照组治疗的基础上给予奥扎格雷钠联合低分子肝素钙治疗。结果治疗后观察组患者NDS、NIHSS及ADL评分明显优于对照组(P<0.05)。治疗后两组患者INR、FIB均优于治疗前(P<0.05)。治疗后观察组患者FIB明显优于对照组(P<0.05)。观察组总有效率为86.7%,对照组为51.1%,两组比较差异具有统计学意义(P<0.05)。两组患者均未见明显的药物不良反应。结论奥扎格雷钠与低分子肝素钙合用治疗进展性脑梗死安全有效。
Objective To investigate the clinical effect of ozagrel combined with low molecular weight heparin on patients with progressive cerebral infarction. Methods 90 patients with progressive cerebral infarction treated in our hospital were randomly divided into observation group and control group. The control group was given routine treatment. The observation group was treated with sodium ozagrel and low molecular weight heparin calcium on the basis of the control group. Results After treatment, the scores of NDS, NIHSS and ADL in observation group were significantly better than those in control group (P <0.05). After treatment, INR and FIB in both groups were better than before treatment (P <0.05). After treatment, FIB in observation group was significantly better than that in control group (P <0.05). The total effective rate was 86.7% in the observation group and 51.1% in the control group, with significant difference between the two groups (P <0.05). No significant adverse drug reaction was seen in both groups. Conclusion Ozagrel sodium combined with low molecular weight heparin calcium is safe and effective in treating progressive cerebral infarction.